Integra LifeSciences cuts 2026 guidance after flooding impact
Integra LifeSciences (IART) lowered its 2026 guidance due to flooding at its Cincinnati facility, reducing revenue and EPS forecasts. Q3 revenue is expected at $410M-$412M, with full-year revenue now projected at $1.634B-$1.654B. The company estimates a $7M Q3 and $15M-$20M Q4 revenue impact. Full operations are expected to resume by Q2 2027, with insurance covering some losses. CEO Stuart Essig anticipates Q3 operating cash flow of over $85M and full-year cash flow of $190M-$200M.
How this was made
The 30-second read
Why it matters
The guidance cut is likely to trigger a sell‑off, though insurance recoveries may cushion earnings later.
Market read
First‑report of a material guidance downgrade for a mid‑cap med‑tech stock; actionable for short‑term traders.
What to watch
Potential upside from alternate supply sources and inventory buffers.
Background
Integra LifeSciences reported flood damage at its Cincinnati plant, prompting a $15‑$20M Q4 revenue hit and a full‑year guidance revision.
Ticker impact
Integra LifeSciences cut its full-year 2026 revenue and earnings guidance due to flood‑related production disruptions.
downward pressure as investors price in weaker outlook
The guidance cut is a primary, material disclosure with $20‑$30M revenue reduction and $0.10 EPS downgrade, prompting immediate sell‑side reaction.
Market effects
Medical device sector may see broader concerns about supply‑chain resilience.
U.S. healthcare stocks could face modest downside pressure.
Limited to U.S. listed med‑tech firms; no global macro effect.
Counterpoint
If insurance recoveries exceed expectations, the impact could be muted.
Key entities
- CompanyIntegra LifeSciences Holdings Corp.
Medical technology firm listed on NASDAQ (IART).
